Description: EarlyBio develops the technology platform eCyto for bedside testing of early and non-stable biomarkers
point of care (66) bedside test (2) earlybio (1) ecyto (1) early biomarker (1)
Siemens researcher and privat investors founded EarlyBio in 2017 to acquire patents and rights on the Magnetic Flow Cytometry technology. The buy-out permits EarlyBio the development and global commercialization of eCyto cell function tests for the point-of-care. EarlyBio will provide functional single cell information to support clinical decision making in critical-care environments. To date, EarlyBio has raised a seed financing round.
Our Magnetic Flow Cytometry technology is covered by 100 patents and patent applications
The eCyto technology allows flow cytometry in whole blood for bedside results in 10-15 minutes.